Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?

Barach, Paul; Fisher, Stacy D.; Adams, Michael; Burstein, Gale R.; Brophy, Patrick D.; Kuo, Dennis Z.; Lipshultz, Steven E.

doi:10.1016/j.ppedcard.2020.101254

Cited by 140 publications

(115 citation statements)

References 66 publications

Supporting

Mentioning

114

Contrasting

Unclassified

Order By: Relevance

“…18 Furthermore, evidence suggests that better coordination of health care in addition to community-based care management approaches will provide suitable alternative to medicine when the healthcare system and, of course, access to health care are thwarted by a pandemic. 19 Our study further underscored the importance of maintaining at least a 30-day supply of prescription and nonprescription medicines to reduce the frequency of health facility visit, especially for those living with chronic illnesses. 20 However, this can compound the strain on incomes already caused by the pandemic.…”

Section: Discussionmentioning

confidence: 60%

Impact of the COVID-19 Pandemic on Consumers’ Access to Essential Medicines in Nigeria

Awucha

Janefrances

Meshach

et al. 2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

COVID-19 is a global pandemic which has seriously impacted the economy of nations. Access to essential medicines is of utmost importance. This study examined the impacts of the COVID-19 pandemic on the ease of access to essential medicines by end users. A cross-sectional survey using electronic questionnaires was conducted on study participants across the 36 states of Nigeria. They were assessed on sociodemographics, health characteristics, and challenges in accessing essential medicines during the COVID-19 pandemic. Data obtained were analyzed using the Statistical Package for the Social Sciences (SPSS version 20, IBM, Armonk, NY) with overall impact of the pandemic operationalized as < 60.0% or ³ 60.0% access to essential medicines by respondents as maximal and minimal impact, respectively. The results showed that 35.2% of the respondents managing chronic illnesses had difficulties accessing essential medicines during the COVID-19 lockdown, with 84.0% experiencing deteriorating chronic health conditions in the light of difficulty in accessing their medicines. The proportion of respondents who sourced for orthodox medicines before COVID-19 lockdown (98.4%) was significantly (P < 0.05) higher than that of those who sourced for the same during the lockdown (89.0%). Increase in cost of medicines was observed by 77.7% of participants, with 73.9% of respondents living with chronic illness affirming that their income was negatively affected by the pandemic. The COVID-19 pandemic had minimal impact on consumers' ability to access essential medicines. However, important challenges identified were poor availability of means of transportation, reduced income, and high cost of medicines, as well as fear of contracting the virus.

show abstract

Section: Discussionmentioning

confidence: 60%

Impact of the COVID-19 Pandemic on Consumers’ Access to Essential Medicines in Nigeria

Awucha

Janefrances

Meshach

et al. 2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…In consequence, when an effective vaccine is introduced fewer people may be willing to accept it resulting in a worsening of the pandemic and further reduce the confidence in already approved and effective vaccines for other diseases. Thus, it is important to build trust and effective communication and restore public confidence in the public health system, which includes being transparent and reporting accurate data timely pertaining to vaccines ( 84 ).…”

Section: Efficacy Of the Vaccine Potential Limitations And Coveragementioning

confidence: 99%

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

et al. 2020

View full text Add to dashboard Cite

A novel coronavirus, which has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first detected in December 2019 in Wuhan China and causes the highly infectious disease referred to as COVID-19. COVID-19 has now spread worldwide to become a global pandemic affecting over 24 million people as of August 26th, 2020 and claimed the life of more than 800,000 people worldwide. COVID-19 is asymptomatic for some individuals and for others it can cause symptoms ranging from flu-like to acute respiratory distress syndrome (ARDS), pneumonia and death. Although it is anticipated that an effective vaccine will be available to protect against COVID-19, at present the world is relying on social distancing and hygiene measures and repurposed drugs. There is a worldwide effort to develop an effective vaccine against SARS-CoV-2 and, as of late August 2020, there are 30 vaccines in clinical trials with over 200 in various stages of development. This review will focus on the eight vaccine candidates that entered Phase 1 clinical trials in mid-May, including AstraZeneca/Oxford's AZD1222, Moderna's mRNA-1273 and Sinovac's CoronaVac vaccines, which are currently in advanced stages of vaccine development. In addition to reviewing the different stages of vaccine development, vaccine platforms and vaccine candidates, this review also discusses the biological and immunological basis required of a SARS-CoV-2 vaccine, the importance of a collaborative international effort, the ethical implications of vaccine development, the efficacy needed for an immunogenic vaccine, vaccine coverage, the potential limitations and challenges of vaccine development. Although the demand for a vaccine far surpasses the production capacity, it will be beneficial to have a limited number of vaccines available for the more vulnerable population by the end of 2020 and for the rest of the global population by the end of 2021.

show abstract

“…The COVID-19 outbreak had a devastating and massive impact on the organization of social activities, as well as a disruptive impact on the organization of care in Italy, with a dramatic reduction in traditional contacts for ensuring care to non COVID-19 diseases [4]. As a matter of fact, hospital admissions for acute myocardial infarction were significantly reduced during the early phase of COVID-19 pandemic across Italy, with a parallel increase in fatality and complication rates [5].…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing)

Boriani

Palmisano²,

Guerra

et al. 2020

Intern Emerg Med

View full text Add to dashboard Cite

COVID-19 outbreak had a major impact on the organization of care in Italy, and a survey to evaluate provision of for arrhythmia during COVID-19 outbreak (March-April 2020) was launched. A total of 104 physicians from 84 Italian arrhythmia centres took part in the survey. The vast majority of participating centres (95.2%) reported a significant reduction in the number of elective pacemaker implantations during the outbreak period compared to the corresponding two months of year 2019 (50.0% of centres reported a reduction of > 50%). Similarly, 92.9% of participating centres reported a significant reduction in the number of implantable cardioverter-defibrillator (ICD) implantations for primary prevention, and 72.6% a significant reduction of ICD implantations for secondary prevention (> 50% in 65.5 and 44.0% of the centres, respectively). The majority of participating centres (77.4%) reported a significant reduction in the number of elective ablations (> 50% in 65.5% of the centres). Also the interventional procedures performed in an emergency setting, as well as acute management of atrial fibrillation had a marked reduction, thus leading to the conclusion that the impact of COVID-19 was disrupting the entire organization of health care, with a massive impact on the activities and procedures related to arrhythmia management in Italy.

show abstract

Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?

Cited by 140 publications

References 66 publications

Impact of the COVID-19 Pandemic on Consumers’ Access to Essential Medicines in Nigeria

Impact of the COVID-19 Pandemic on Consumers’ Access to Essential Medicines in Nigeria

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Impact of COVID-19 pandemic on the clinical activities related to arrhythmias and electrophysiology in Italy: results of a survey promoted by AIAC (Italian Association of Arrhythmology and Cardiac Pacing)

Contact Info

Product

Resources

About